Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.
Debureaux PE, Kulasekararaj AG, Cacace F, Silva BGP, Calado RT, Barone F, Sicre de Fontbrune F, Prata PH, Soret J, Sica M, Notaro R, Scheinberg P, Mallikarjuna V, Gandhi S, Large J, Risitano AM, Peffault de Latour R, Frieri C; Severe Aplastic Anemia Working Party of the European Group for Bone Marrow Transplantation. Debureaux PE, et al. Among authors: risitano am. Bone Marrow Transplant. 2021 Oct;56(10):2600-2602. doi: 10.1038/s41409-021-01372-0. Epub 2021 Jul 5. Bone Marrow Transplant. 2021. PMID: 34226670 No abstract available.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. Hillmen P, et al. Among authors: risitano am. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. N Engl J Med. 2006. PMID: 16990386 Free article. Clinical Trial.
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, Ricci P, Alfinito F, Camera A, Gianfaldoni G, Amendola A, Boschetti C, Di Bona E, Fratellanza G, Barbano F, Rodeghiero F, Zanella A, Iori AP, Selleri C, Luzzatto L, Rotoli B. Risitano AM, et al. Blood. 2009 Apr 23;113(17):4094-100. doi: 10.1182/blood-2008-11-189944. Epub 2009 Jan 29. Blood. 2009. PMID: 19179465 Free article.
Paroxysmal nocturnal hemoglobinuria and eculizumab.
Luzzatto L, Risitano AM, Notaro R. Luzzatto L, et al. Among authors: risitano am. Haematologica. 2010 Apr;95(4):523-6. doi: 10.3324/haematol.2009.017848. Haematologica. 2010. PMID: 20378572 Free PMC article. No abstract available.
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.
Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH. Pulsipher MA, et al. Among authors: risitano am. Biol Blood Marrow Transplant. 2011 Mar;17(3):291-9. doi: 10.1016/j.bbmt.2010.10.028. Epub 2010 Oct 27. Biol Blood Marrow Transplant. 2011. PMID: 21034841 Free PMC article.
Eculizumab treatment modifies the immune profile of PNH patients.
Alfinito F, Ruggiero G, Sica M, Udhayachandran A, Rubino V, Della Pepa R, Palatucci AT, Annunziatella M, Notaro R, Risitano AM, Terrazzano G. Alfinito F, et al. Among authors: risitano am. Immunobiology. 2012 Jul;217(7):698-703. doi: 10.1016/j.imbio.2011.11.009. Epub 2011 Dec 3. Immunobiology. 2012. PMID: 22206707
207 results